B
PACB icon

Braidwell’s Pacific Biosciences PACB Stock Holding History

Braidwell’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,097,300
Closed -$12.7M – 89
2023
Q1 		$12.7M Buy
+1,097,300
New +$10.9M 0.42% 64

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Braidwell's PACB Position: Q2 2023 in Review

Braidwell sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 1,097,300 shares — an estimated $12.7M sold.

Braidwell first reported a position in PACB in Q1 2023 and held it in 1 quarter. The position peaked at $12.7M in Q1 2023. 271 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Braidwell reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Braidwell sold 1,097,300 Pacific Biosciences shares in Q2 2023, an estimated $12.7M.
  • Braidwell first reported a position in Pacific Biosciences in Q1 2023 and held it in 1 quarter.
  • Braidwell's Pacific Biosciences position peaked at $12.7M in Q1 2023.
  • 271 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.